Copay Assist Programs Creating Problems in Health Care Markets

Share this content:
Copay Assist Programs Creating Problems in Health Care Markets
Copay Assist Programs Creating Problems in Health Care Markets

TUESDAY, Oct. 11, 2016 (HealthDay News) -- Despite offering assistance to individuals who cannot afford expensive medications, copay assistance programs create broader problems in health care markets, according to an Ideas and Opinions piece published online Oct. 11 in the Annals of Internal Medicine.

Noting that Mylan recently offered patients coupons to cover part of their out-of-pocket costs for the EpiPen, Peter A. Ubel, M.D., from Duke University in Durham, N.C., and Peter B. Bach, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, explored the impact of copay assistance for expensive drugs.

The authors report that copay assistance is not a solution to increasing drug costs, but is part of the problem. Copay assistance reduces price pressure by reducing the public outcry over outrageous drug prices. In addition, copay assistance undermines the effect of out-of-pocket expenses on health care utilization, pressuring insurance companies to increase prices and threatening low-cost insurance plans. Furthermore, pharmaceutical companies offer assistance for prescriptions that patients fill before their insurance is activated; coupons can be used to speed patients to their out-of-pocket maximum (insurers cannot distinguish between payments from patients and copay coupons). Copay assistance programs also reduce negotiating leverage for insurers and keep patients from acting as consumers who scrutinize the cost and quality of health care services.

"Policymakers should also consider adopting value-based drug pricing as a long-term solution to high copays and thus copay assistance," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »